Pmv Pharmaceuticals
Yahoo Finance • 12 months ago
PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights
Updated data from Phase 1 PYNNACLE clinical trial of PC14586 presented at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics demonstrated responses across multiple tumor types with median duration of... Full story
Yahoo Finance • last year
PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation
Updated PC14586 Phase 1 data presented today as a late-breaking poster at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsConfirmed responses observed in multiple tumor types including ovarian, brea... Full story
Yahoo Finance • last year
PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL Webinar
PRINCETON, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced... Full story
Yahoo Finance • last year
PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Late-breaking poster presentation to highlight updated Phase 1 clinical data of PC14586, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors that have a TP53 Y220C mutationCompany to host KOL... Full story
Yahoo Finance • last year
PMV Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Highlights
Continued progress in the ongoing Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation; next update is expected in 2H 2023Commence... Full story
Yahoo Finance • 2 years ago
PMV Pharmaceuticals Reports Full Year 2022 Financial Results and Corporate Highlights
Continued progress in ongoing Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation; PMV expects to provide next clinical update in... Full story
Yahoo Finance • 2 years ago
15 Most Shorted Stocks Right Now
In this article, we discuss the 15 most shorted stocks right now. If you want to read about some more shorted stocks, go directly to 5 Most Shorted Stocks Right Now. The stock market has been volatile in the past few months as soaring inf... Full story
Yahoo Finance • 2 years ago
PMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights
Enrollment continued in the Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation Phase 1b combination trial with Merck evaluating... Full story
Yahoo Finance • 2 years ago
PMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of Directors
CRANBURY, N.J., Nov. 04, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced... Full story
Yahoo Finance • 2 years ago
10 Most Shorted Stocks to Watch in July
In this article, we discuss the 10 most shorted stocks to watch in July. If you want to skip our analysis of the US stock market, go directly to the 5 Most Shorted Stocks to Watch in July. According to data shared by S3 Partners, short se... Full story
Yahoo Finance • 2 years ago
PMV Pharmaceuticals Announces a Clinical Trial Collaboration with Merck to Evaluate PC14586 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
CRANBURY, N.J., July 18, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, to... Full story
Yahoo Finance • 2 years ago
PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare Conference
CRANBURY, N.J., June 08, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, to... Full story
Yahoo Finance • 2 years ago
PMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a p53 Y220C Mutation
Overall response rate (ORR) of 32% (8/25) achieved in higher dose cohorts per RECIST v1.1 Partial responses observed across six distinct tumor typesData featured as an oral presentation at ASCO; Company to host investor event via webcast... Full story
Yahoo Finance • 2 years ago
PMV Pharmaceuticals Reports First Quarter 2022 Financial Results and Corporate Highlights
Oral presentation at 2022 ASCO annual meeting to highlight initial data from ongoing Phase 1/2 PYNNACLE study of PC14586 in patients with advanced solid tumors CRANBURY, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (... Full story
Yahoo Finance • 3 years ago
PMV Pharmaceuticals to Present PC14586 Phase 1 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Oral presentation at ASCO to highlight initial data from ongoing Phase 1 study of PC14586, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors that have a p53 Y220C mutation CRANBURY, N.J.,... Full story
